UNIGE document Scientific Article
previous document  unige:30597  next document
add to browser collection

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis

Ruperto, Nicolino
Brunner, Hermine I
Quartier, Pierre
Constantin, Tamás
Wulffraat, Nico
Horneff, Gerd
Brik, Riva
McCann, Liza
show hidden authors show all authors [1 - 36]
Published in New England Journal of Medicine. 2012, vol. 367, no. 25, p. 2396-406
Abstract Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti-interleukin-1β monoclonal antibody, in two trials.
Keywords AdolescentAnti-Inflammatory Agents, Non-Steroidal/therapeutic useAntibodies, Monoclonal/adverse effects/therapeutic useArthritis, Juvenile Rheumatoid/complications/drug therapyChildChild, PreschoolDouble-Blind MethodDrug Therapy, CombinationFemaleGlucocorticoids/therapeutic useHumansInfection/chemically inducedInterleukin-1beta/antagonists & inhibitorsKaplan-Meier EstimateMacrophage Activation Syndrome/etiologyMaleMethotrexate/therapeutic useNeutropenia/chemically inducedThrombocytopenia/chemically induced
PMID: 23252526
Full text
Article (Published version) (527 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Pathogénèse du syndrome néphrotique idiopathique de l'enfant (180)
(ISO format)
RUPERTO, Nicolino et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. In: New England Journal of Medicine, 2012, vol. 367, n° 25, p. 2396-406. doi: 10.1056/NEJMoa1205099 https://archive-ouverte.unige.ch/unige:30597

529 hits

0 download


Deposited on : 2013-10-23

Export document
Format :
Citation style :